KPIs & Operating Metrics(New)
Growth Metrics

Bristol Myers Squibb (BMY) Gross Margin (2016 - 2026)

Bristol Myers Squibb has reported Gross Margin over the past 18 years, most recently at 70.22% for Q1 2026.

  • Quarterly Gross Margin fell 270.0% to 70.22% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 70.45% through Mar 2026, down 1.0% year-over-year, with the annual reading at 71.08% for FY2025, 0.0% changed from the prior year.
  • Gross Margin was 70.22% for Q1 2026 at Bristol Myers Squibb, up from 67.23% in the prior quarter.
  • Over five years, Gross Margin peaked at 79.02% in Q3 2022 and troughed at 61.01% in Q4 2024.
  • The 5-year median for Gross Margin is 75.13% (2024), against an average of 73.92%.
  • Year-over-year, Gross Margin tumbled -1507bps in 2024 and then surged 622bps in 2025.
  • A 5-year view of Gross Margin shows it stood at 77.27% in 2022, then fell by -2bps to 76.08% in 2023, then dropped by -20bps to 61.01% in 2024, then increased by 10bps to 67.23% in 2025, then grew by 4bps to 70.22% in 2026.
  • Per Business Quant, the three most recent readings for BMY's Gross Margin are 70.22% (Q1 2026), 67.23% (Q4 2025), and 71.89% (Q3 2025).